Last reviewed · How we verify
DA-2802
DA-2802 is a selective activator of estrogen receptor beta (ERβ) that modulates estrogen signaling to treat menopausal symptoms and potentially other hormone-related conditions.
DA-2802 is a selective activator of estrogen receptor beta (ERβ) that modulates estrogen signaling to treat menopausal symptoms and potentially other hormone-related conditions. Used for Menopausal vasomotor symptoms (hot flashes and night sweats).
At a glance
| Generic name | DA-2802 |
|---|---|
| Also known as | tenofovir disoproxil orotate |
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Selective estrogen receptor beta agonist |
| Target | Estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Women's Health / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
DA-2802 selectively binds to and activates estrogen receptor beta, a subtype of estrogen receptors that is distinct from the classical estrogen receptor alpha. By preferentially targeting ERβ, the drug aims to provide therapeutic benefits of estrogen signaling while potentially minimizing risks associated with non-selective estrogen receptor activation, such as proliferative effects on breast and endometrial tissue.
Approved indications
- Menopausal vasomotor symptoms (hot flashes and night sweats)
Common side effects
- Headache
- Hot flashes
- Nausea
Key clinical trials
- Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients (PHASE3)
- Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |